Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Identifieur interne : 000C73 ( Main/Exploration ); précédent : 000C72; suivant : 000C74

Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Auteurs : Xuesen Zhao [République populaire de Chine] ; Mohit Sehgal [États-Unis] ; Zhifei Hou [République populaire de Chine] ; Junjun Cheng [États-Unis] ; Sainan Shu [États-Unis] ; Shuo Wu [États-Unis] ; Fang Guo [États-Unis] ; Sylvain J. Le Marchand [États-Unis] ; Hanxin Lin [Canada] ; Jinhong Chang [États-Unis] ; Ju-Tao Guo [République populaire de Chine]

Source :

RBID : pubmed:29263263

Descripteurs français

English descriptors

Abstract

Interferon-induced transmembrane proteins (IFITMs) are restriction factors that inhibit the infectious entry of many enveloped RNA viruses. However, we demonstrated previously that human IFITM2 and IFITM3 are essential host factors facilitating the entry of human coronavirus (HCoV) OC43. In a continuing effort to decipher the molecular mechanism underlying IFITM differential modulation of HCoV entry, we investigated the roles of structural motifs important for IFITM protein posttranslational modifications, intracellular trafficking, and oligomerization in modulating the entry of five HCoVs. We found that three distinct mutations in IFITM1 or IFITM3 converted the host restriction factors to enhance entry driven by the spike proteins of severe acute respiratory syndrome coronavirus (SARS-CoV) and/or Middle East respiratory syndrome coronavirus (MERS-CoV). First, replacement of IFITM3 tyrosine 20 with either alanine or aspartic acid to mimic unphosphorylated or phosphorylated IFITM3 reduced its activity to inhibit the entry of HCoV-NL63 and -229E but enhanced the entry of SARS-CoV and MERS-CoV. Second, replacement of IFITM3 tyrosine 99 with either alanine or aspartic acid reduced its activity to inhibit the entry of HCoV-NL63 and SARS-CoV but promoted the entry of MERS-CoV. Third, deletion of the carboxyl-terminal 12 amino acid residues from IFITM1 enhanced the entry of MERS-CoV and HCoV-OC43. These findings suggest that these residues and structural motifs of IFITM proteins are key determinants for modulating the entry of HCoVs, most likely through interaction with viral and/or host cellular components at the site of viral entry to modulate the fusion of viral envelope and cellular membranes.IMPORTANCE The differential effects of IFITM proteins on the entry of HCoVs that utilize divergent entry pathways and membrane fusion mechanisms even when using the same receptor make the HCoVs a valuable system for comparative investigation of the molecular mechanisms underlying IFITM restriction or promotion of virus entry into host cells. Identification of three distinct mutations that converted IFITM1 or IFITM3 from inhibitors to enhancers of MERS-CoV or SARS-CoV spike protein-mediated entry revealed key structural motifs or residues determining the biological activities of IFITM proteins. These findings have thus paved the way for further identification of viral and host factors that interact with those structural motifs of IFITM proteins to differentially modulate the infectious entry of HCoVs.

DOI: 10.1128/JVI.01535-17
PubMed: 29263263


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.</title>
<author>
<name sortKey="Zhao, Xuesen" sort="Zhao, Xuesen" uniqKey="Zhao X" first="Xuesen" last="Zhao">Xuesen Zhao</name>
<affiliation wicri:level="3">
<nlm:affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, China zhaoxuesen@ccmu.edu.cn ju-tao.guo@bblumberg.org.</nlm:affiliation>
<country wicri:rule="url">République populaire de Chine</country>
<wicri:regionArea>Beijing Ditan Hospital, Capital Medical University, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sehgal, Mohit" sort="Sehgal, Mohit" uniqKey="Sehgal M" first="Mohit" last="Sehgal">Mohit Sehgal</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hou, Zhifei" sort="Hou, Zhifei" uniqKey="Hou Z" first="Zhifei" last="Hou">Zhifei Hou</name>
<affiliation wicri:level="3">
<nlm:affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Ditan Hospital, Capital Medical University, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Cheng, Junjun" sort="Cheng, Junjun" uniqKey="Cheng J" first="Junjun" last="Cheng">Junjun Cheng</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shu, Sainan" sort="Shu, Sainan" uniqKey="Shu S" first="Sainan" last="Shu">Sainan Shu</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Wu, Shuo" sort="Wu, Shuo" uniqKey="Wu S" first="Shuo" last="Wu">Shuo Wu</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Guo, Fang" sort="Guo, Fang" uniqKey="Guo F" first="Fang" last="Guo">Fang Guo</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Le Marchand, Sylvain J" sort="Le Marchand, Sylvain J" uniqKey="Le Marchand S" first="Sylvain J" last="Le Marchand">Sylvain J. Le Marchand</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Biology, Drexel University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biology, Drexel University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lin, Hanxin" sort="Lin, Hanxin" uniqKey="Lin H" first="Hanxin" last="Lin">Hanxin Lin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology and Laboratory Medicine, Western University, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Chang, Jinhong" sort="Chang, Jinhong" uniqKey="Chang J" first="Jinhong" last="Chang">Jinhong Chang</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Guo, Ju Tao" sort="Guo, Ju Tao" uniqKey="Guo J" first="Ju-Tao" last="Guo">Ju-Tao Guo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA zhaoxuesen@ccmu.edu.cn ju-tao.guo@bblumberg.org.</nlm:affiliation>
<country wicri:rule="url">République populaire de Chine</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<wicri:noRegion>Pennsylvania</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29263263</idno>
<idno type="pmid">29263263</idno>
<idno type="doi">10.1128/JVI.01535-17</idno>
<idno type="wicri:Area/PubMed/Corpus">000A42</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A42</idno>
<idno type="wicri:Area/PubMed/Curation">000A42</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A42</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000998</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000998</idno>
<idno type="wicri:Area/Ncbi/Merge">002E88</idno>
<idno type="wicri:Area/Ncbi/Curation">002E88</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002E88</idno>
<idno type="wicri:Area/Main/Merge">000C75</idno>
<idno type="wicri:Area/Main/Curation">000C73</idno>
<idno type="wicri:Area/Main/Exploration">000C73</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.</title>
<author>
<name sortKey="Zhao, Xuesen" sort="Zhao, Xuesen" uniqKey="Zhao X" first="Xuesen" last="Zhao">Xuesen Zhao</name>
<affiliation wicri:level="3">
<nlm:affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, China zhaoxuesen@ccmu.edu.cn ju-tao.guo@bblumberg.org.</nlm:affiliation>
<country wicri:rule="url">République populaire de Chine</country>
<wicri:regionArea>Beijing Ditan Hospital, Capital Medical University, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Sehgal, Mohit" sort="Sehgal, Mohit" uniqKey="Sehgal M" first="Mohit" last="Sehgal">Mohit Sehgal</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hou, Zhifei" sort="Hou, Zhifei" uniqKey="Hou Z" first="Zhifei" last="Hou">Zhifei Hou</name>
<affiliation wicri:level="3">
<nlm:affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Beijing Ditan Hospital, Capital Medical University, Beijing</wicri:regionArea>
<placeName>
<settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Cheng, Junjun" sort="Cheng, Junjun" uniqKey="Cheng J" first="Junjun" last="Cheng">Junjun Cheng</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shu, Sainan" sort="Shu, Sainan" uniqKey="Shu S" first="Sainan" last="Shu">Sainan Shu</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Wu, Shuo" sort="Wu, Shuo" uniqKey="Wu S" first="Shuo" last="Wu">Shuo Wu</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Guo, Fang" sort="Guo, Fang" uniqKey="Guo F" first="Fang" last="Guo">Fang Guo</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Le Marchand, Sylvain J" sort="Le Marchand, Sylvain J" uniqKey="Le Marchand S" first="Sylvain J" last="Le Marchand">Sylvain J. Le Marchand</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Biology, Drexel University, Philadelphia, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biology, Drexel University, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lin, Hanxin" sort="Lin, Hanxin" uniqKey="Lin H" first="Hanxin" last="Lin">Hanxin Lin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pathology and Laboratory Medicine, Western University, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Chang, Jinhong" sort="Chang, Jinhong" uniqKey="Chang J" first="Jinhong" last="Chang">Jinhong Chang</name>
<affiliation wicri:level="2">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<placeName>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Guo, Ju Tao" sort="Guo, Ju Tao" uniqKey="Guo J" first="Ju-Tao" last="Guo">Ju-Tao Guo</name>
<affiliation wicri:level="1">
<nlm:affiliation>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania, USA zhaoxuesen@ccmu.edu.cn ju-tao.guo@bblumberg.org.</nlm:affiliation>
<country wicri:rule="url">République populaire de Chine</country>
<wicri:regionArea>Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown, Pennsylvania</wicri:regionArea>
<wicri:noRegion>Pennsylvania</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint>
<date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amino Acid Motifs</term>
<term>Amino Acid Substitution</term>
<term>Antigens, Differentiation (genetics)</term>
<term>Antigens, Differentiation (metabolism)</term>
<term>Cell Line, Tumor</term>
<term>Coronavirus (genetics)</term>
<term>Coronavirus (metabolism)</term>
<term>Humans</term>
<term>Membrane Proteins (genetics)</term>
<term>Membrane Proteins (metabolism)</term>
<term>Mutation, Missense</term>
<term>Protein Multimerization</term>
<term>RNA-Binding Proteins (genetics)</term>
<term>RNA-Binding Proteins (metabolism)</term>
<term>Spike Glycoprotein, Coronavirus (genetics)</term>
<term>Spike Glycoprotein, Coronavirus (metabolism)</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Antigènes de différenciation (génétique)</term>
<term>Antigènes de différenciation (métabolisme)</term>
<term>Coronavirus (génétique)</term>
<term>Coronavirus (métabolisme)</term>
<term>Glycoprotéine de spicule des coronavirus (génétique)</term>
<term>Glycoprotéine de spicule des coronavirus (métabolisme)</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Motifs d'acides aminés</term>
<term>Multimérisation de protéines</term>
<term>Mutation faux-sens</term>
<term>Protéines de liaison à l'ARN (génétique)</term>
<term>Protéines de liaison à l'ARN (métabolisme)</term>
<term>Protéines membranaires (génétique)</term>
<term>Protéines membranaires (métabolisme)</term>
<term>Pénétration virale</term>
<term>Substitution d'acide aminé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Antigens, Differentiation</term>
<term>Membrane Proteins</term>
<term>RNA-Binding Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Antigens, Differentiation</term>
<term>Membrane Proteins</term>
<term>RNA-Binding Proteins</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Antigènes de différenciation</term>
<term>Coronavirus</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines de liaison à l'ARN</term>
<term>Protéines membranaires</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Antigènes de différenciation</term>
<term>Coronavirus</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Protéines de liaison à l'ARN</term>
<term>Protéines membranaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Amino Acid Motifs</term>
<term>Amino Acid Substitution</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Mutation, Missense</term>
<term>Protein Multimerization</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Motifs d'acides aminés</term>
<term>Multimérisation de protéines</term>
<term>Mutation faux-sens</term>
<term>Pénétration virale</term>
<term>Substitution d'acide aminé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Interferon-induced transmembrane proteins (IFITMs) are restriction factors that inhibit the infectious entry of many enveloped RNA viruses. However, we demonstrated previously that human IFITM2 and IFITM3 are essential host factors facilitating the entry of human coronavirus (HCoV) OC43. In a continuing effort to decipher the molecular mechanism underlying IFITM differential modulation of HCoV entry, we investigated the roles of structural motifs important for IFITM protein posttranslational modifications, intracellular trafficking, and oligomerization in modulating the entry of five HCoVs. We found that three distinct mutations in IFITM1 or IFITM3 converted the host restriction factors to enhance entry driven by the spike proteins of severe acute respiratory syndrome coronavirus (SARS-CoV) and/or Middle East respiratory syndrome coronavirus (MERS-CoV). First, replacement of IFITM3 tyrosine 20 with either alanine or aspartic acid to mimic unphosphorylated or phosphorylated IFITM3 reduced its activity to inhibit the entry of HCoV-NL63 and -229E but enhanced the entry of SARS-CoV and MERS-CoV. Second, replacement of IFITM3 tyrosine 99 with either alanine or aspartic acid reduced its activity to inhibit the entry of HCoV-NL63 and SARS-CoV but promoted the entry of MERS-CoV. Third, deletion of the carboxyl-terminal 12 amino acid residues from IFITM1 enhanced the entry of MERS-CoV and HCoV-OC43. These findings suggest that these residues and structural motifs of IFITM proteins are key determinants for modulating the entry of HCoVs, most likely through interaction with viral and/or host cellular components at the site of viral entry to modulate the fusion of viral envelope and cellular membranes.
<b>IMPORTANCE</b>
The differential effects of IFITM proteins on the entry of HCoVs that utilize divergent entry pathways and membrane fusion mechanisms even when using the same receptor make the HCoVs a valuable system for comparative investigation of the molecular mechanisms underlying IFITM restriction or promotion of virus entry into host cells. Identification of three distinct mutations that converted IFITM1 or IFITM3 from inhibitors to enhancers of MERS-CoV or SARS-CoV spike protein-mediated entry revealed key structural motifs or residues determining the biological activities of IFITM proteins. These findings have thus paved the way for further identification of viral and host factors that interact with those structural motifs of IFITM proteins to differentially modulate the infectious entry of HCoVs.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
<li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region>
<li>Pennsylvanie</li>
</region>
<settlement>
<li>Pékin</li>
</settlement>
</list>
<tree>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Zhao, Xuesen" sort="Zhao, Xuesen" uniqKey="Zhao X" first="Xuesen" last="Zhao">Xuesen Zhao</name>
</noRegion>
<name sortKey="Guo, Ju Tao" sort="Guo, Ju Tao" uniqKey="Guo J" first="Ju-Tao" last="Guo">Ju-Tao Guo</name>
<name sortKey="Hou, Zhifei" sort="Hou, Zhifei" uniqKey="Hou Z" first="Zhifei" last="Hou">Zhifei Hou</name>
</country>
<country name="États-Unis">
<region name="Pennsylvanie">
<name sortKey="Sehgal, Mohit" sort="Sehgal, Mohit" uniqKey="Sehgal M" first="Mohit" last="Sehgal">Mohit Sehgal</name>
</region>
<name sortKey="Chang, Jinhong" sort="Chang, Jinhong" uniqKey="Chang J" first="Jinhong" last="Chang">Jinhong Chang</name>
<name sortKey="Cheng, Junjun" sort="Cheng, Junjun" uniqKey="Cheng J" first="Junjun" last="Cheng">Junjun Cheng</name>
<name sortKey="Guo, Fang" sort="Guo, Fang" uniqKey="Guo F" first="Fang" last="Guo">Fang Guo</name>
<name sortKey="Le Marchand, Sylvain J" sort="Le Marchand, Sylvain J" uniqKey="Le Marchand S" first="Sylvain J" last="Le Marchand">Sylvain J. Le Marchand</name>
<name sortKey="Shu, Sainan" sort="Shu, Sainan" uniqKey="Shu S" first="Sainan" last="Shu">Sainan Shu</name>
<name sortKey="Wu, Shuo" sort="Wu, Shuo" uniqKey="Wu S" first="Shuo" last="Wu">Shuo Wu</name>
</country>
<country name="Canada">
<noRegion>
<name sortKey="Lin, Hanxin" sort="Lin, Hanxin" uniqKey="Lin H" first="Hanxin" last="Lin">Hanxin Lin</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C73 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C73 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29263263
   |texte=   Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29263263" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021